Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Rein Therapeutics. The associated price target remains the same with $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Rein Therapeutics’ potential in addressing significant market needs. The company’s lead asset, LTI-03, is designed to tackle idiopathic pulmonary fibrosis (IPF) through a novel dual mechanism, which could offer superior efficacy compared to existing treatments. This innovative approach targets a multi-billion-dollar market with substantial unmet needs, and the potential for LTI-03 to become best-in-class is a key driver behind the Buy rating.
Moreover, the recent lifting of the clinical hold on the U.S. Phase 2 RENEW trial and expansion of European trial infrastructure are positive developments that support the company’s global trial execution. Rein Therapeutics has also secured flexible financing options to sustain its operations, which, along with promising early clinical data and scientific validation, positions the company well for future growth. These factors contribute to the belief that the current market capitalization does not fully reflect the company’s potential, justifying the Buy rating and a $10 price target.
According to TipRanks, Folkes is an analyst with an average return of -2.1% and a 38.44% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Achieve Life Sciences, and Eupraxia Pharmaceuticals.
In another report released on November 3, Brookline Capital Markets also upgraded the stock to a Buy with a $6.00 price target.